Cost
Gross Carrying Amount
Gross carrying amount [member]
Restricted Stock Units [Line Items]
Restricted Stock Units [Line Items]
Restricted stock units line items
Summary of Intangible Assets Amortized
Disclosure Of Intangible Assets Amortization Explanatory [Table Text Block]
Disclosure of intangible assets amortization.
Performance obligations [axis]
Performance obligations [axis]
Time deposits
Times Deposits Non Current
Times deposits, non-current.
Fair value of share options granted
Weighted average fair value at measurement date, other equity instruments granted
NON-CURRENT LIABILITIES
Non-current liabilities [abstract]
Summary of Capital Commitments
Disclosure Of Capital Commitments Explanatory [Table Text Block]
Disclosure of capital commitments.
Equity-settled share-based compensation expense
Key management personnel compensation, share-based payment
Paid in capital and reserve funds
Paid In Capital And Reserve Funds
Paid in capital and reserve funds.
Interest receivable
Interest receivable
Proceeds from issuance of ordinary shares for institutional investors, net of issuance cost
Proceeds From Issuance Of Ordinary Shares For Institutional Investors, Net Of Issuance Cost
Proceeds From Issuance Of Ordinary Shares For Institutional Investors, Net Of Issuance Cost
Relationship
Description of nature of related party relationship
Time deposits
Deposits From Bank
Deposits from bank.
Withholding tax rate
Withholding Tax Rate
Withholding tax rate.
Disclosure of performance obligations [line items]
Disclosure of performance obligations [line items]
Summary of Trade and Notes Payables
Disclosure Of Trade And Other Payables Table [Text Block]
Disclosure of trade and other payables table text block.
Wages and salaries
Wages and salaries
Effect of non-deductible expenses
Tax effect of expense not deductible in determining taxable profit (tax loss)
Other payables
Other Payables [Member]
Other payables.
Authorized (in shares)
Number of shares authorised
Capital requirements [axis]
Capital requirements [axis]
Disclosure Of Financial Liabilities [Line Items]
Disclosure of financial liabilities [line items]
Summary of Deferred Revenue from Contract Liabilities
Disclosure Of Deferred Revenue From Customer Contract Liabilities [Text Block]
Disclosure Of Deferred Revenue From Customer Contract Liabilities
TRADE RECEIVABLES
Disclosure of trade and other receivables [text block]
Follow-On Public Offering
Follow On Public Offering [Member]
Follow-on public offering.
Disclosure of voluntary change in accounting policy [abstract]
Impairment loss of non-financial assets
Impairment loss recognised in profit or loss
Summary of Other Payables and Accruals
Disclosure Of Detailed Information About Other Payables And Accruals Explanatory [Table Text Block]
Disclosure of detailed information about other payables and accruals.
Specified development milestones
Specified Development Milestones [Member]
Specified development milestones.
Range [axis]
Range [axis]
Surcharge rate
Surcharge Rate
Surcharge rate.
Exchange realignment
Increase (Decrease) Through Effect Of Exchange Realignment In Foreign Exchange Rate
Increase (decrease) through effect of exchange realignment in foreign exchange rate.
Finance income
Finance income
Granted during the year (in dollars per share)
Weighted average exercise price of share options granted in share-based payment arrangement
Financial instruments, class [member]
Financial instruments, class [member]
Legend Biotech
Legend Biotech [Member]
Legend Biotech
Trading Symbol
Trading Symbol
Weighted average grant date fair value
Weighted Average Grant Date Fair Value [Roll Forward]
Weighted Average Grant Date Fair Value
Nanjing Probio Biotech Co., Ltd.
Nanjing Probio Biotech Co., Ltd. [Member]
Nanjing Probio Biotech Co Ltd.
Summary of Lease Expense
Lessee Lease Expenses [Text Block]
Lessee lease expenses text block.
Trade and other payables [abstract]
At the statutory blended US federal and state income tax rate of 24.3% (2022 and 2021: 28.1%)
Tax Expense Income At Statutory Blended Income Tax Rate
Tax expense income at statutory blended income tax rate.
Cilta-cel
Cilta-Cel Clinical Development [Member]
Cilta-Cel Clinical Development
All Currencies
All Currencies [Domain]
Cash flows from (used in) operations before changes in working capital
Cash flows from (used in) operations before changes in working capital
Collaboration prepaid leases
Collaboration prepaid leases
Collaboration prepaid leases
If US$ weakens against EUR
U S Dollar Weakens Against E U R [Member]
US$ weakens against EUR.
SHARE OPTION SCHEME
Disclosure of share-based payment arrangements [text block]
Period that share option scheme remains in force
Period Of Share Option Scheme Remain In Force
Period of share option scheme remain in force.
Effect of foreign exchange rate changes, net
Effect of exchange rate changes on cash and cash equivalents
Due to related parties
Amounts payable, related party transactions
Private Placement for Institutional Investor
Private Placement For Institutional Investor [Member]
Private Placement For Institutional Investor
Disclosure Of Property Plant And Equipment [Line Items]
Disclosure of detailed information about property, plant and equipment [line items]
Interest paid classified as operating cash flows
Interest paid, classified as operating activities
TRADE PAYABLES
Disclosure of trade and other payables [text block]
Total liabilities and equity
Equity and liabilities
REVENUE, OTHER INCOME AND GAINS
Disclosure Of Revenue Other Income And Gains Explanatory [Text Block]
Disclosure of revenue, other income and gains.
OPERATING SEGMENT INFORMATION
Disclosure of operating segments [text block]
Local Phone Number
Local Phone Number
Forfeited during the year (in dollars per share)
Weighted average exercise price of share options forfeited in share-based payment arrangement
Disposals
Disposals, intangible assets other than goodwill
Contract liabilities
Contract liabilities (Current)
Current contract liabilities
Temporary difference, unused tax losses and unused tax credits [member]
Temporary difference, unused tax losses and unused tax credits [member]
Maturity [axis]
Less than 1 years
Maturity [axis]
Cash and bank balances
Cash
COLLABORATION INVENTORIES
Disclosure of inventories [text block]
Financial assets, class [member]
Financial assets, class [member]
Financial liabilities
Description of accounting policy for financial liabilities [text block]
Construction in progress
Construction in progress [member]
Foreign currency exchange loss/(gain), net
Adjustments for unrealised foreign exchange losses (gains)
Vested during the year (in shares)
Number of other equity instruments exercised or vested in share-based payment arrangement
Increase in pledged deposits, net
Increase Decrease In Pledged Deposits Net
Increase decrease in pledged deposits net.
Total current liabilities
Current liabilities
OTHER COMPREHENSIVE INCOME
Exchange differences on translation [abstract]
Useful economic lives of intangible assets
Useful life measured as period of time, intangible assets other than goodwill
Document Accounting Standard
Document Accounting Standard
Geographical areas [axis]
Geographical areas [axis]
Deferred tax carry forward period
Deferred Tax Carry Forward Period
Deferred tax carry forward period.
ICFR Auditor Attestation Flag
ICFR Auditor Attestation Flag
Other comprehensive loss:
Other comprehensive income [abstract]
Fair value measurement
Description of accounting policy for fair value measurement [text block]
Prepayment
Prepayment [Member]
Prepayment.
Entity's total for probability of default [member]
Entity's total for probability of default [member]
Research and development credit
Tax Effects Research And Development Credit
Tax effects research and development credit.
Total non-current assets
Non-current assets
Summary of Compensation of Key Management Personnel
Disclosure Of Amounts Incurred For Compensation Of Key Management Personnel Explanatory [Table Text Block]
Disclosure of amounts incurred for compensation of key management personnel.
Summary of Inventories
Disclosure Of Detailed Information About Inventories Explanatory [Table Text Block]
The disclosure of detailed information about inventories.
Decrease in pledged deposits
Decrease In Pledged Deposits
Decrease in pledged deposits.
Loss on disposal of property, plant and equipment
Gains (losses) on disposals of property, plant and equipment
Exercisable at December 31 (in dollars per share)
Weighted average exercise price of share options exercisable in share-based payment arrangement
Consideration paid for shared services
Services received, related party transactions
Total ordinary shareholders’ equity
Equity attributable to owners of parent
Issuance of ordinary shares for registered direct offering, net of issuance cost (in shares)
Issuance Of Ordinary Shares For Registered Direct Offering Net Of Issuance Cost Number Of Shares In Issue
Issuance Of Ordinary Shares For Registered Direct Offering Net Of Issuance Cost Number Of Shares In Issue
Disclosure Of Fair Value Valuation Of Warrant Liability [Line Items]
Disclosure Of Fair Value Valuation Of Warrant Liability [Line Items]
Disclosure of fair value valuation of warrant liability.
Belgium
BELGIUM
ISSUED BUT NOT YET EFFECTIVE INTERNATIONAL FINANCIAL REPORTING STANDARDS
Disclosure of expected impact of initial application of new standards or interpretations [text block]
Proceeds from issuance of ordinary shares for follow on public offering, net of issuance costs
Proceeds From Issuance Of Ordinary Shares For Follow On Public Offering, Net Of Issuance Costs
Proceeds from issuance of ordinary shares for follow on public offering, net of issuance costs.
Lessee's incremental borrowing rate applied to lease liabilities (in percent)
Lessees Incremental Borrowing Rate Applied To Lease Liabilities
Lessees incremental borrowing rate applied to lease liabilities.
Sales of products and sales-based royalties from related parties
Revenue From Sale Of Products And Sales Based Royalties From Related Party Transactions
Revenue From Sale Of Products And Sales Based Royalties From Related Party Transactions
Total
Key management personnel compensation
Computer and office equipment
Computer And Office Equipment [Member]
Computer and office equipment.
NOTES TO THE CONSOLIDATED STATEMENT OF CASH FLOWS
Disclosure of cash flow statement [text block]
(Increase)/decrease in collaboration inventories
Adjustments for decrease (increase) in inventories
Disclosure Of Detailed Information About Borrowings [Table]
Disclosure of detailed information about borrowings [table]
Security Exchange Name
Security Exchange Name
Total tax charge/(credit) for the year
Current and deferred tax relating to items credited (charged) directly to equity
Leasehold land
Leasehold Land [Member]
Leasehold land.
Total
Contract liabilities
Disclosure Of Significant Investments In Subsidiaries [Line Items]
Disclosure of subsidiaries [line items]
Within financing activities
Cash Outflow For Leases Within Financing Activities
Cash outflow for leases within financing activities.
Deferred Tax Assets [Roll Forward]
Deferred Tax Assets [Roll Forward]
Deferred Tax Assets
Trade and other receivables [abstract]
Genscript Netherlands
Genscript Netherlands [Member]
Genscript Netherlands.
Document Type
Document Type
Depreciation of right-of-use assets
Adjustments For Depreciation Of Right Of Use Assets
Adjustments for depreciation of right-of-use assets.
Area of manufacturing facility expected to be leased (in square feet)
Area of Manufacturing Facility Expected to be Leased
Area of Manufacturing Facility Expected to be Leased
Reserves
Other reserves
Finance costs
Total
Finance costs
Legend Biotech Ireland Limited (“Legend Ireland”)
Legend Biotech Ireland Limited [Member]
Legend Biotech Ireland Limited.
Research and development credit
Tax Rate Effect On Research And Development Credit
Tax rate effect on research and development credit.
3 - 4 years
Later than three years and not later than four years [member]
Number of options (in shares)
At January 1 (in shares)
At December 31 (in shares)
Number of share options outstanding in share-based payment arrangement
Financial assets at fair value through profit or loss
Financial assets at value through profit or loss
Current financial assets at fair value through profit or loss
Cash received from withdrawal of financial assets measured at fair value through profit or loss
Cash Received From Withdrawal Of Financial Assets At Fair Value Through Profit Or Loss
Cash received from withdrawal of financial assets at fair value through profit or loss.
Percentage of foreign currency forward exchange contract
Percentage Of Foreign Currency Forward Exchange Contract
Percentage of foreign currency forward exchange contract.
2,000,000,000 shares of $0.0001 each
Authorized Share Capital
Authorized share capital.
Summary of Liabilities Measured at Fair Value
Disclosure of fair value measurement of liabilities [text block]
Audit Information [Abstract]
Audit Information
PROPERTY, PLANT AND EQUIPMENT
Disclosure of property, plant and equipment [text block]
Liabilities from Financing Activities [Roll Forward]
Liabilities from Financing Activities [Roll Forward]
Liabilities from Financing Activities
Disclosure Of Property Plant And Equipment [Table]
Disclosure of detailed information about property, plant and equipment [table]
Risks [member]
Risks [member]
Issuance of ordinary shares for follow-on public offering, net of issuance cost (in shares)
Issuance Of Ordinary Shares For Follow On Public Offering Net Of Issuance Cost Number Of Shares In Issue
Issuance of ordinary shares for follow-on-public offering, net of issuance cost, number of shares in issue.
Performance obligation satisfaction period
Performance Obligation Satisfaction Period
Performance Obligation Satisfaction Period
Profit or loss [abstract]
Top of Range
Top of range [member]
Milestone payment not eligible to receive based on subsequent change in development plan
Milestone Payment Not Eligible To Receive Based On Subsequent Change In Development Plan
Milestone payment not eligible to receive based on subsequent change in development plan.
Title of 12(b) Security
Title of 12(b) Security
Total gains
Other gains (losses)
Disclosure Of Disaggregation Of Revenue From Contracts With Customers [Table]
Disclosure of disaggregation of revenue from contracts with customers [table]
Issuance of ordinary shares for registered direct offering, net of issuance cost
Issuance Of Ordinary Shares For Registered Direct Offering Net Of Issuance
Issuance Of Ordinary Shares For Registered Direct Offering Net Of Issuance
Stock-based compensation income tax charge/(benefit)
Tax Effect Of Option Income Tax Expense Benefit
Tax effect of option income tax expense (benefit).
Computer and office equipment
Office equipment [member]
Profit/loss split percentage
Cost-Sharing and Profit (Loss) Split
Cost-Sharing and Profit (Loss) Split
Issuance of ordinary shares for private placements, net of issuance cost
Issuance Of Ordinary Share Relating To Private Placement For Institutional Investor
Issuance of ordinary shares relating to private placement for institutional investor.
Interest on lease liabilities
Interest expense
Interest expense on lease liabilities
Finished goods
Current finished goods
Financial liabilities at fair value
Financial liabilities at fair value through profit or loss
Financial liabilities at fair value through profit or loss
Changes from financing cash flows
Increase (decrease) through financing cash flows, liabilities arising from financing activities
One Customer
One Customer [Member]
One Customer
1 - 2 years
Later than one year and not later than two years [member]
Entity Interactive Data Current
Entity Interactive Data Current
Expected volatility (%)
Volatility
Expected volatility, share options granted
Government grants
Non-current
Non-current government grants
Disclosure Of Notes To Consolidated Statement Of Cash Flows [Abstract]
Disclosure of notes to the consolidated statement of cash flows.
Fair value loss on warrant
Fair value loss/(gain) of the warrant liability
Warrant Liability Fair Value Loss (Gain) Recorded
Warrant liability fair value loss recorded.
Attributable to:
Comprehensive income attributable to [abstract]
Quoted prices in active markets (Level 1)
Level 1 of fair value hierarchy [member]
Entity Well-known Seasoned Issuer
Entity Well-known Seasoned Issuer
Other expenses
Other expenses, by nature
Government Grants [Abstract]
Government grants.
Disclosure Of Other Payables And Accruals [Abstract]
Disclosure of other payables and accruals.
Ordinary equity holders of the parent
Loss attributable to ordinary equity holders of the parent, used in the basic earnings per share calculation
Profit (loss), attributable to owners of parent
Legend Biotech USA Incorporated (“Legend USA”)
Legend Biotech U S A Incorporated [Member]
Legend Biotech USA Incorporated.
Disclosure Of Significant Investments In Subsidiaries [Table]
Disclosure of subsidiaries [table]
Summary of Share Options Outstanding Under the Scheme
Disclosure of number and weighted average exercise prices of share options [text block]
Provision for inventory reserve
Adjustments For Inventory Reserve Provision
Adjustments For Inventory Reserve Provision
Summary of Prepayments, Other Receivables and Other Assets
Disclosure Of Detailed Information About Prepayments Other Receivables And Other Assets Explanatory [Table Text Block]
Disclosure of detailed information about prepayments, other receivables and other assets.
Fair value of share options granted
Weighted average fair value at measurement date, share options granted
Software
Computer software [member]
Entity Incorporation, State or Country Code
Entity Incorporation, State or Country Code
Genscript Biotech Corporation
Genscript Biotech Corporation [Member]
Genscript Biotech Corporation ("Genscript")
Effect of tax rate differences in other countries and regions
Tax rate effect of foreign tax rates
2019/11/29 - 2019/12/09
2019/11/29 - 2019/12/09 [Member]
2019/11/29 - 2019/12/09
Summary of Intangible Assets
Disclosure of detailed information about intangible assets [text block]
RELATED PARTY TRANSACTIONS
Disclosure of related party [text block]
Disclosure of classes of share capital [abstract]
Cash receipts of investment income
Cash Receipts Of Investment Income Classified As Investing Activities
Cash receipts of investment income classified as investing activities.
Tax payable
Current tax liabilities
Collaboration agreement, number of customers
Collaboration Agreement, Number of Customers
Collaboration Agreement, Number of Customers
If US$ strengthens against EUR
U S Dollar Strengthens Against E U R [Member]
US$ strengthens against EUR.
Genscript Group
Genscript Group [Member]
Genscript Group.
Transaction price, amount constrained at inception
Transaction Price, Constrained Amount
Transaction Price, Constrained Amount
Summary of Carrying Amounts of The Right-of-use Assets and Movements
Disclosure of quantitative information about right-of-use assets [text block]
Auditor Location
Auditor Location
Legend Biotech HK Limited (“Legend HK”)
Legend Biotech H K Limited [Member]
Legend Biotech HK Limited.
Profit Loss Before Tax [Table]
Profit Loss Before Tax [Table]
Schedule disclosing information related to profit loss before tax.
INCOME TAX
Disclosure of income tax [text block]
Exercise of Warrant
Exercise Of Warrant [Member]
Exercise Of Warrant
Classes of financial instruments [axis]
Classes of financial instruments [axis]
Dividend yield (%)
Dividend
Expected dividend as percentage, share options granted
Total equity
Beginning balance
Ending balance
Equity
Summary of Deferred Government Grants
Disclosure Of Deferred Government Grants Explanatory [Table Text Block]
Disclosure of deferred government grants.
Principal activities
Description of nature of entity's operations and principal activities
Components of equity [axis]
Components of equity [axis]
Service concession arrangements [axis]
Service concession arrangements [axis]
Document Shell Company Report
Document Shell Company Report
Credit risk
Credit risk [member]
Major Components Of Tax Expense Income [Line Items]
Major Components Of Tax Expense Income [Line Items]
Major components of tax expense income.
Collaboration interest-bearing advanced funding
Collaboration interest-bearing advanced funding [Member]
Collaboration interest-bearing advanced funding
Significant unobservable inputs (Level 3)
Level 3 of fair value hierarchy [member]
Time deposits
Times Deposits Current And Noncurrent
Times deposits current and noncurrent.
Total liabilities
Total liabilities
Liabilities
Issued and fully paid (in shares)
Number of shares issued and fully paid
Net other comprehensive income that may be reclassified to profit or loss in subsequent periods
Other comprehensive income that will be reclassified to profit or loss, net of tax
Collaboration cost of revenue
Cost of sales
Trade receivables
Trade Receivable [Member]
Trade receivable.
Authorized:
Authorised [Abstract]
Authorised.
China
CHINA
Lease terms and estimated useful lives of right-of-use assets
Lease Terms And Estimated Useful Lives Of Right Of Use Assets
Lease terms and estimated useful lives of right of use assets.
Binomial Model
Binomial Model [Member]
Binomial model.
Aggregated measurement [member]
Aggregated measurement [member]
Denominated in USD
United States of America, Dollars
FAIR VALUE AND FAIR VALUE HIERARCHY OF FINANCIAL INSTRUMENTS
Disclosure of fair value of financial instruments [text block]
Deferred (note 20)
Deferred tax relating to items credited (charged) directly to equity
Accumulated depreciation
Accumulated amortization
Accumulated depreciation and amortisation [member]
Useful life of property, plant and equipment
Useful life measured as period of time, property, plant and equipment
Government grants
Government Grants Received From Local Government Authorities
Government grants received from local government authorities.
State rate change
Tax rate effect from change in tax rate
Novartis
Novartis [Member]
Novartis
Fair value per share of options granted (in dollars per share)
Weighted average share price, share options granted
Lease liabilities
Lease liability
Lease liabilities [member]
Financial liabilities at amortized cost
Financial liabilities at amortised cost
Beginning balance (in shares)
Ending balance (in shares)
Share Capital And Share Premium Number Of Shares In Issue
Share capital and share premium, number of shares in issue.
Net cash provided by financing activities
Cash flows from (used in) financing activities
Disclosure of performance obligations [table]
Disclosure of performance obligations [table]
Summary of Monitoring Capital Using Gearing Ratio
Disclosure Of Detailed Information About Monitoring Capital Using Gearing Ratio Explanatory [Table Text Block]
Disclosure of detailed information about monitoring capital using gearing ratio.
Disclosure of detailed information about property, plant and equipment [abstract]
Collaboration interest-bearing advanced funding
Interest expense on borrowings
Warrant
Warrant [Member]
Warrant
Summary of Interest-Bearing Loans and Borrowings
Disclosure of detailed information about borrowings [text block]
Ireland
IRELAND
Depreciation of right-of-use assets
Depreciation charge of right-of-use assets
Depreciation, right-of-use assets
Summary of Shares
Disclosure of share capital, reserves and other equity interest [text block]
Collaboration interest-bearing advanced funding
Non-current portion of non-current borrowings
Proceeds from exercise of warrants
Proceeds from exercise of warrants
Time deposits
Times Deposits
Times deposits.
COMMITMENTS AND CONTINGENCIES
Disclosure of commitments [text block]
Number of options
Number of RSU
Number of Options [Roll Forward]
Number of Options
Deductible temporary differences
Deductible temporary differences for which no deferred tax asset is recognised
Service concession arrangements [member]
Service concession arrangements [member]
Disclosure Of Movements In Deferred Tax Assets And Liabilities
Disclosure Of Movements In Deferred Tax Assets And Liabilities Explanatory [Text Block]
Disclosure Of Movements In Deferred Tax Assets And Liabilities Explanatory
Reclassification of vested restricted share units
Increase (Decrease) Through Reclassification Of Vested Restricted Stock Equity
Increase (decrease) through reclassification of vested restricted stock, equity.
Accretion of interest recognized during the year
Increase Of Lease Liabilities Balance
Increase of lease liabilities balance.
Accrued payroll
Accrued Payroll
Accrued payroll.
Hong Kong
HONG KONG
Disclosure Of Prepayments Other Receivables And Other Assets [Table]
Disclosure Of Prepayments Other Receivables And Other Assets [Table]
Disclosure of prepayments, other receivables and other assets.
Genscript USA Holdings Inc
Genscript U S A Holdings Inc [Member]
Genscript USA Holdings Inc.
OTHER COMPREHENSIVE INCOME FOR THE YEAR, NET OF TAX
Other comprehensive income
Global Economic Conditions
Global Economic Conditions [Text Block]
Global Economic Conditions
Concentrations of risk [axis]
Concentrations of risk [axis]
Issuance costs
Share issue related cost
Disclosure Of Cash And Cash Equivalents Time Deposits And Pledged Deposits [Line Items]
Disclosure Of Cash And Cash Equivalents Time Deposits And Pledged Deposits [Line Items]
Disclosure of cash and cash equivalents, time deposits and pledged deposits.
Other revenue
Other revenue
Other revenue
Lease liabilities long term
Non-current portion
Non-current lease liabilities
Entity Emerging Growth Company
Entity Emerging Growth Company
Non-cash additions to collaboration prepaid leases from collaboration partner
Assets Leased From Collaboration Partner
Assets Leased From Collaboration Partner
Cash and bank balances
Cash and bank balances at central banks
Restricted Stock Units [Table]
Restricted Stock Units [Table]
Restricted stock units table.
Proceeds from issue of ordinary shares
Proceeds from issue of ordinary shares
Statement of financial position [abstract]
Disclosure Of Reconciliation Of Liabilities Arising From Financing Activities [Line Items]
Disclosure of reconciliation of liabilities arising from financing activities [line items]
Disclosure Of Number And Weighted Average Remaining Contractual Life Of Outstanding Share Options [Table]
Disclosure of number and weighted average remaining contractual life of outstanding share options [table]
Classes of share capital [axis]
Classes of share capital [axis]
Summary of Revenue
Disclosure of geographical areas [text block]
Other Income and Gains
Disclosure of other operating income [text block]
Collaboration inventories
Total collaboration inventories
Current inventories
Deferred Tax Liabilities [Roll Forward]
Deferred Tax Liabilities [Roll Forward]
Deferred Tax Liabilities
Other receivables due from related parties
Due from related parties
Amounts receivable, related party transactions
Summary of Sensitivity to Reasonably Possible Change in Exchange Rates
Disclosure Of Detailed Information About Sensitivity To Reasonably Possible Change In Exchange Rates Explanatory [Table Text Block]
Disclosure of detailed information about the sensitivity to reasonably possible change in exchange rates.
Disclosure Of Intangible Assets [Line Items]
Disclosure of detailed information about intangible assets [line items]
Ranges [member]
Ranges [member]
Entity Address, Postal Zip Code
Entity Address, Postal Zip Code
Types of risks [axis]
Types of risks [axis]
Summary of Exercise Prices and Exercise Periods of Share Options Outstanding
Disclosure of range of exercise prices of outstanding share options [text block]
Borrowings by name [axis]
Borrowings by name [axis]
Transaction price
Total
Transaction Price
Estimated transaction price related to contract.
Private Placement Transactions
Private Placement Transactions [Member]
Private Placement Transactions
Total amount recognized in profit or loss
Lease Expense Amount Recognized In Profit Or Loss
Lease expense amount recognized in profit or loss.
Aggregated time bands [member]
Aggregated time bands [member]
Business Contact
Business Contact [Member]
Summary of Financial Liabilities
Disclosure of financial liabilities [text block]
Summary of Trade Receivables
Disclosure Of Detailed Information Of Trade Receivables Table [Text Block]
Disclosure of detailed information of trade receivables.
Disclosure of expected impact of initial application of new standards or interpretations [abstract]
Building
Buildings
Lease buildings
Buildings [member]
DEFERRED TAX
Disclosure of deferred taxes [text block]
EQUITY
Equity [abstract]
Other
Other Finance Gains
Other finance gains.
Administrative expenses
Administrative expenses
Jiangsu GenScript Probio Biotech Co., Ltd.
Jiangsu GenScript Probio Biotech Co., Ltd. [Member]
Jiangsu Genscript Probio Biotech Co., Ltd.
Short-term leases
Cash Outflow For Short Term Leases
Cash outflow for short term leases.
CORPORATE INFORMATION
Disclosure of notes and other explanatory information [text block]
The disclosure of notes and other explanatory information as part of a complete set of financial statements.
Machinery and equipment
Machinery and equipment
Machinery [member]
Collaboration inventories
Description of accounting policy for measuring inventories [text block]
Warrant liability
Balance, beginning of the period
Balance, end of the period
Warrant liability
Share-based payment arrangements [member]
Share-based payment arrangements [member]
2019/12/31 – 2028/12/30
2019/12/31 – 2028/12/30 [Member]
2019/12/31 – 2028/12/30
Trade payables
Trade Payables [Member]
Trade payables.
Share Capital [Roll Forward]
Share Capital [Roll Forward]
Share Capital
Total revenue
Revenue
Non-current assets
Non-current assets other than financial instruments, deferred tax assets, post-employment benefit assets, and rights arising under insurance contracts
RESTRICTED SHARE UNITS
Restricted Stock Units Explanatory [Text Block]
Restricted stock units.
Beginning balance
Ending balance
Liabilities arising from financing activities
Document Transition Report
Document Transition Report
Exercise of share options (in shares)
Exercise Of Share Option Number Of Shares In Issue
Exercise of share option number of shares in issue.
APPROVAL OF THE CONSOLIDATED FINANCIAL STATEMENTS
Disclosure of authorisation of financial statements [text block]
Difference in intangible assets amortization
Difference In Intangible Assets Amortization [Member]
Difference In Intangible Assets Amortization
Property, plant and equipment [member]
Property, plant and equipment [member]
Granted during the year (in shares)
Number of other equity instruments granted in share-based payment arrangement
Entity's total for related parties [member]
Entity's total for related parties [member]
Disclosure Of Intangible Assets [Table]
Disclosure of detailed information about intangible assets [table]
Share premium
Share premium [member]
Liquidity Risk
Liquidity risk [member]
Transfers
Increase (decrease) through transfers from (to) investment property, property, plant and equipment
Disclosure of terms and conditions of share-based payment arrangement [abstract]
Entity Address, Country
Entity Address, Country
Gearing ratio
Capital Gearing Ratio
Gearing ratio.
Depreciation of property, plant and equipment
Adjustments for depreciation expense
Diluted (in dollars per share)
Diluted earnings (loss) per share
Impairment of financial assets
Description of accounting policy for impairment of financial assets [text block]
Aggregate exercise price of warrant
Aggregate Exercise Price Of Warrants
Aggregate Exercise Price Of Warrants
Classes of current inventories [abstract]
Classes of current inventories [abstract]
Summary of Fair Value Valuation of Warrant Liability
Disclosure Of Information Of Inputs Used In Fair Value Valuation Of Warrant Liability Explanatory [Table Text Block]
Disclosure of information of inputs used in fair value valuation of warrant liability.
Summary of Calculations of Basic and Diluted Loss per Share
Earnings per share [text block]
Performance obligations [member]
Performance obligations [member]
Time deposits
Time Deposits [Member]
Time deposits.
Disclosure Of Cash And Cash Equivalents Time Deposits And Pledged Deposits [Abstract]
Disclosure of cash and cash equivalents, time deposits and pledged deposits.
Disclosure Of Fair Value Measurement Of Assets And Liabilities [Abstract]
Disclosure of fair value measurement of assets and liabilities.
Non-cash additions to collaboration interest-bearing advanced funding
Adjustments to Collaboration Interest-Bearing Advanced Funding, Increase (Decrease)
Adjustments to Collaboration Interest-Bearing Advanced Funding, Increase (Decrease)
Disclosure Of Transactions Between Related Parties [Line Items]
Disclosure of transactions between related parties [line items]
Collaboration revenue
Total collaboration revenue
Collaboration Revenue
Collaboration Revenue
2023/03/31 - 2032/03/30
2023/03/31 - 2032/03/30 [Member]
2023/03/31 - 2032/03/30
Disclosure of detailed information about borrowings [abstract]
Prepaid expenses
Prepayments
Prepayments
Document Financial Statement Error Correction [Flag]
Document Financial Statement Error Correction [Flag]
Disclosure Of Operating Segments [Table]
Disclosure of operating segments [table]
Other non-current liabilities
Other non-current liabilities
Granted during the year (in dollars per share)
Weighted average exercise price of other equity instruments granted in share-based payment arrangement
Fair value gains on financial assets measured at fair value change through profit or loss
Adjustments for fair value losses (gains)
Granted during the year (in shares)
Number of share options granted in share-based payment arrangement
Customers [member]
Customers [member]
Exchange realignment
Increase (decrease) through net exchange differences, property, plant and equipment
Company
Name of subsidiary
2019/07/01 – 2028/08/29
2019/07/01 – 2028/08/29 [Member]
2019/07/01 – 2028/08/29
Intangible assets
Description of accounting policy for intangible assets other than goodwill [text block]
Non-Collaboration Assets Leased
Right Of Use Assets Excluding Collaboration [Member]
Right Of Use Assets Excluding Collaboration
2022/08/27 – 2031/08/26
2022/08/27 – 2031/08/26 [Member]
2022/08/27 – 2031/08/26
Cash and cash equivalents
Cash And Cash Equivalent [Member]
Cash and cash equivalents.
Document Period End Date
Document Period End Date
Additions
Increase In Lease Liabilities
Increase in lease liabilities.
Deferred tax charged to the statement of profit or loss during the year
Deferred tax expense (income) recognised in profit or loss related to deferred tax assets
Deferred tax expense (income) recognised in profit or loss related to deferred tax assets
Summary of Transactions with Related Parties
Disclosure of transactions between related parties [text block]
Expected life of options (year)
Weighted average remaining contractual life of outstanding share options
At January 1 (in dollars per share)
At December 31 (in dollars per share)
Weighted average exercise price of share options outstanding in share-based payment arrangement
Tax losses and credits
Unused tax losses for which no deferred tax asset recognised
Disclosure Of Quantitative Information About Rightofuse Assets [Line Items]
Disclosure of quantitative information about right-of-use assets [line items]
Stock-based compensation income tax charge/(benefit)
Tax Rate Effect Of Option Income Tax Benefit
Tax rate effect of option income tax benefit.
Preferential tax rate in other countries and regions
Tax Rate Effect Of Foreign Preferential Tax Rates
Tax Rate Effect Of Foreign Preferential Tax Rates
RSU
Restricted Stock Units [Member]
Restricted stock units member.
Summary of Finance Costs
Disclosure of finance cost [text block]
Tax losses and deductible temporary differences not recognized
Tax rate effect of tax losses
Property, plant and equipment
Property, plant and equipment, beginning balance
Property, plant and equipment, ending balance
Property, plant and equipment
Forfeited during the year (in dollars per share)
Weighted average exercise price of other equity instruments forfeited in share-based payment arrangement
Share premium before issue expenses
Share Premium Before Issue Expenses
Share premium before issue expenses.
Construction in progress
Construction Payment Payable In Future
Construction payment payable in future.
NET INCREASE IN CASH AND CASH EQUIVALENTS
Increase (decrease) in cash and cash equivalents before effect of exchange rate changes
Payments
Total
Cash outflow for leases
Entity's total for subsidiaries [member]
Entity's total for subsidiaries [member]
Short-term employee benefits
Key management personnel compensation, short-term employee benefits
Others
Other tax rate effects for reconciliation between accounting profit and tax expense (income)
Remaining unsatisfied performance obligation
Amounts expected to be recognized as revenue
Transaction price allocated to remaining performance obligations
Deferred tax assets, beginning balance
Deferred tax assets, ending balance
Deferred tax assets
Forfeited during the year (in shares)
Number of share options forfeited in share-based payment arrangement
Disclosure Of Disaggregation Of Revenue From Contracts With Customers [Line Items]
Disclosure of disaggregation of revenue from contracts with customers [line items]
Tax losses and deductible temporary differences not recognized
Tax Losses And Deductible Temporary Differences Not Recognized
Tax losses and deductible temporary differences not recognized.
Specified net trade sales milestones
Specified Net Trade Sales Milestones [Member]
Specified net trade sales milestones.
Transportation equipment
Vehicles [member]
Purchase of financial assets measured at fair value through profit or loss
Purchase Of Financial Assets At Fair Value Through Profit Or Loss Classified As Investing Activities
Purchase of financial assets at fair value through profit or loss classified as investing activities.
Application Acceptance
Application Acceptance [Member]
Application Acceptance
Other non-current assets
Other non-current non-financial assets
Exercised during the year (in dollars per share)
Weighted average exercise price of share options exercised in share-based payment arrangement
Collaboration revenue
Collaboration Revenue [Member]
Collaboration Revenue
Statement of cash flows [abstract]
Government grants
Description of accounting policy for government grants [text block]
TOTAL COMPREHENSIVE LOSS FOR THE YEAR
Comprehensive income
Date of incorporation
Date Of Incorporation
Date of incorporation.
Cash and cash equivalents
Cash and cash equivalents at beginning of year
CASH AND CASH EQUIVALENTS AT END OF YEAR
Cash and cash equivalents
Cash and cash equivalents
Maximum percent of future taxable profits that can be indefinitely offset
Deferred Tax Asset, Maximum Percentage of Future Taxable Profits For Indefinite Offsetting
Deferred Tax Asset, Maximum Percentage of Future Taxable Profits For Indefinite Offsetting
Document Annual Report
Document Annual Report
Lease liabilities, repayment term
Lease Liabilities Repayment Term
Lease liabilities, repayment term.
Percentage of number of shares issued
Percentage Of Number Of Number Shares Issued
Percentage of number of number shares issued.
(Increase)/decrease in trade receivables
Adjustments for decrease (increase) in trade accounts receivable
Total non-current liabilities
Non-current liabilities
Exercised during the year (in shares)
Number of share options exercised in share-based payment arrangement
Cover [Abstract]
Genscript USA Incorporated
Genscript U S A Incorporated [Member]
Genscript USA Incorporated.
Cash and cash equivalents
Description of accounting policy for determining components of cash and cash equivalents [text block]
If US$ strengthens against RMB
U S Dollar Strengthens Against R M B [Member]
US$ strengthens against RMB.
Lessee, lease terms
Lessee Leasing Arrangements Leases Term
Lessee leasing arrangements leases term.
Total assets
Total assets
Assets
United States of America
United States of America
UNITED STATES
Disclosure Fair Value Measurement Hierarchy Of Financial Instruments [Line Items]
Disclosure Fair Value Measurement Hierarchy Of Financial Instruments [Line Items]
Disclosure fair value measurement hierarchy of financial instruments.
Basic earnings per share [abstract]
Increase/(decrease) in contract liabilities (current)
Adjustments For Increase (Decrease) In Contract Liabilities, Current
Adjustments For Increase (Decrease) In Contract Liabilities, Current
Foreign currency translation reserve
Reserve of exchange differences on translation [member]
Purchase of financial assets measured at amortized cost
Purchase Of Financial Assets Measured At Amortized Cost
Purchase of financial assets measured at amortized cost.
Gains:
Gains (losses) on financial instruments [abstract]
CASH FLOWS FROM FINANCING ACTIVITIES
Cash flows from (used in) financing activities [abstract]
PREPAYMENTS, OTHER RECEIVABLES AND OTHER ASSETS
Disclosure Of Prepayments Other Receivables And Other Assets Explanatory [Text Block]
Disclosure of prepayments, other receivables and other assets.
Depreciation provided during the year
Depreciation, property, plant and equipment
Interest Bearing Loans
11.0% Interest Bearing Loans [Member]
11.0% Interest Bearing Loans
Pledged deposits
Pledged Deposits [Member]
Pledged deposits.
Share capital
Number of shares in issue
Issued capital [member]
License revenue - transitional adjustment
Revenue From Licensing Of Intellectual Property, Transitional Adjustment [Member]
Revenue From Licensing Of Intellectual Property, Transitional Adjustment
2 - 3 Years
Later than two years and not later than three years [member]
Time deposits
Time Deposits Policy [Text Block]
Time deposits.
Entity Current Reporting Status
Entity Current Reporting Status
Weighted average share price used in share option fair value valuation model (in dollars per share)
Weighted Average Share Price Used In Share Option Fair Value
Weighted average share price used in share option fair value.
Distributable retained earnings
Retained earnings
Disclosure Of Fair Value Of Financial Instruments [Abstract]
Disclosure of fair value of financial instruments.
Weighted average share price for share options in share-based payment arrangement exercised during period (in dollars per share)
Weighted average share price for share options in share-based payment arrangement exercised during period at date of exercise
Weighted average number of ordinary shares in issue during the year used in the basic earnings per share calculation (in shares)
Weighted average number of ordinary shares used in calculating basic earnings per share
Right of use assets
Right-of-use assets [member]
Specified regulatory milestones
Specified Regulatory Milestones [Member]
Specified regulatory milestones.
Losses available for offsetting against future taxable profits
Unused tax losses [member]
Summary of Nature of Related Party Relationship
Summary Of Nature Of Related Party Relationship [Table Text Block]
Summary of nature of related party relationship.
2023/05/05 - 2032/05/04
2023/05/05 - 2032/05/04 [Member]
2023/05/05 - 2032/05/04
2020/11/29 – 2029/11/28
2020/11/29 – 2029/11/28 [Member]
2020/11/29 – 2029/11/28
Lease [Abstract]
Lease [Abstract]
Lease abstract.
Proceeds from issuance of ordinary shares and warrant relating to private placement for an institutional investor
Proceeds From Issuance Of Ordinary Shares And Warrant Relating To Private Placement For An Institutional Investor
Proceeds from issuance of ordinary shares and warrant relating to private placement for an institutional investor.
Financial assets at amortized cost
Financial assets at amortised cost
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Summary of Other Non-Current Assets
Disclosure Of Other Noncurrent Assets Table [Text Block]
Disclosure of other noncurrent assets table text block.
Employee benefit expense (including directors’ remuneration):
Employee Benefit Expense Excluding Directors Remuneration [Abstract]
Employee Benefit Expense Excluding Directors Remuneration [Abstract]
Less: Pledged deposits
Short-term deposits, classified as cash equivalents
(Decrease)/increase in trade payables
Adjustments for increase (decrease) in trade and other payables
CURRENT LIABILITIES
Current liabilities [abstract]
Warrant liability
Warranty contingent liability [member]
Summary of Reconciliation of Tax Expense Applicable to Loss Before Tax at the Statutory Rates
Detailed Disclosure Of Reconciliation Of Tax Expense Applicable To Loss Before Tax At Statutory Rate [Table Text Block]
Detailed disclosure of reconciliation of tax expense applicable to loss before tax at the statutory rate.
Finance income
Adjustments for finance income
Disclosure Of Transaction Price Allocated To Remaining Performance Obligations [Line Items]
Disclosure of transaction price allocated to remaining performance obligations [line items]
Entity Voluntary Filers
Entity Voluntary Filers
Reconciliation Of Changes In Deferred Tax Assets and Liabilities [Line Items]
Reconciliation Of Changes In Deferred Tax Assets and Liabilities [Line Items]
Reconciliation of changes in deferred tax assets and liabilities.
Disclosure of detailed information about intangible assets [abstract]
Income tax received
Income taxes paid (refund), classified as operating activities
Disclosure of reserves within equity [abstract]
Share capital [member]
Share capital [member]
Other payables
Other payables
State rate change
Tax effect from change in tax rate
Disclosure Of Prepayments Other Receivables And Other Assets [Abstract]
Disclosure of prepayments, other receivables and other assets.
Undiscounted finance lease payments to be received
Undiscounted finance lease payments to be received
Summary of Depreciation Calculated on Straight-line Basis Over Estimated Useful Lives of Assets
Disclosure of depreciation and amortisation expense [text block]
Amount of trade receivables subject to concentration of credit risk
Risk exposure associated with instruments sharing characteristic
Disclosure Of Financial Assets [Line Items]
Disclosure of financial assets [line items]
Amortization provided during the year
Amortisation, intangible assets other than goodwill
Deferred tax assets and liabilities [abstract]
Income tax benefit/(expense)
Tax charge/(benefit) at the Company’s effective rate
Tax expense (income)
Other
Other finance income
Statement of Changes in Equity [Roll Forward]
Statement of Changes in Equity [Roll Forward]
Statement of Changes in Equity
Disclosure Of Detailed Information About Lease Liabilities [Table]
Disclosure Of Detailed Information About Lease Liabilities [Table]
Disclosure of detailed information about lease liabilities.
Summary of Estimated Useful Lives of Right-of-Use Assets
Disclosure Of Estimated Useful Lives Of Right Of Use Assets Explanatory [Table Text Block]
Disclosure of estimated useful lives of right-of-use assets.
2023/05/13 - 2032/05/12
2023/05/13 - 2032/05/12 [Member]
2023/05/13 - 2032/05/12
Geographical
Geographical [Axis]
2023/05/02 - 2032/05/01
2023/05/02 - 2032/05/01 [Member]
2023/05/02 - 2032/05/01
NON-CURRENT ASSETS
Non-current assets [abstract]
RESERVES
Disclosure of reserves within equity [text block]
Disclosure Of Significant Accounting Judgements And Estimates [Abstract]
Disclosure of significant accounting judgements and estimates.
Summary of Tax Charges
Detailed Disclosure Of Tax Charges [Table Text Block]
Detailed disclosure of tax charges.
Other Collaboration Receivables
Other Collaboration Receivables
Other Collaboration Receivables
Summary of Lease Liabilities Measured at Present Value of Lease Payments to be Made Over Lease Term
Lessee Lease Liabilities [Text Block]
Lessee lease liabilities text block.
Tax charge/(benefit) at the Company’s effective rate
Average effective tax rate
Accrued expense
Accrued Expense
Accrued expense.
LOSS PER SHARE ATTRIBUTABLE TO ORDINARY EQUITY HOLDERS OF THE PARENT
Disclosure of earnings per share [text block]
Share capital
Issued ordinary shares/paid-up capital
363,822,069 (2022: 330,134,480) ordinary shares of $0.0001 each
Issued capital
Other receivables
Other receivables
Legend Biotech Belgium B.V. (“Legend Belgium”)
Legend Biotech Belgium B V [Member]
Legend Biotech Belgium B.V.
Probability of default [axis]
Probability of default [axis]
Exercise of share options
Increase (decrease) through exercise of options, equity
2022/03/29 – 2031/03/28
2022/03/29 – 2031/03/28 [Member]
2022/03/29 – 2031/03/28
Place and date of incorporation
Place And Date Of Incorporation Of Business Of Subsidiary
Place and date of incorporation of business of subsidiary.
Less: Pledged deposits
Pledged Short Term Deposits
Pledged short-term deposits.
Interest on lease payments
Interest On Lease Payments Classified As Operating Activities
Interest on lease payments classified as operating activities.
Former employee damages demanded
Former Employee Damages Demand
Former employee damages demand.
Difference allowance in excess of related depreciation
Difference Allowance In Excess Of Related Depreciation [Member]
Difference Allowance In Excess Of Related Depreciation
Disclosure Of Transactions Between Related Parties [Table]
Disclosure of transactions between related parties [table]
Income tax paid
Income taxes paid, classified as operating activities
Contract liabilities
Contract liabilities (Non Current)
Non-current contract liabilities
Disclosure of operating segments [abstract]
SHARE CAPITAL AND SHARE PREMIUM
Disclosure of classes of share capital [text block]
Variable consideration
Transaction Price, Variable Consideration
Transaction Price, Variable Consideration
Effect of non-deductible expenses
Tax rate effect of expense not deductible in determining taxable profit (tax loss)
Others
Other tax effects for reconciliation between accounting profit and tax expense (income)
Basic (in dollars per share)
Basic earnings (loss) per share
LOSS BEFORE TAX
Disclosure of profit (loss) from operating activities [text block]
Total
Other non-current assets
Disclosure of transactions between related parties [abstract]
Disclosure Of Fair Value Valuation Of Warrant Liability [Table]
Disclosure Of Fair Value Valuation Of Warrant Liability [Table]
Disclosure of fair value valuation of warrant liability.
2020/07/02 – 2029/07/01
2020/07/02 – 2029/07/01 [Member]
2020/07/02 – 2029/07/01
VAT recoverable
Value added tax receivables
Disclosure of detailed information about financial instruments [abstract]
Research and development costs
Description of accounting policy for research and development expense [text block]
Issuance of ordinary shares for follow-on public offering, net of issuance cost
Issuance Of Ordinary Shares For Follow On Public Offering Net Of Issuance Cost
Issuance Of Ordinary Shares For Follow On Public Offering Net Of Issuance Cost
Profit Loss Before Tax Arrived After Charging And Crediting
Profit Loss Before Tax Arrived After Charging And Crediting [Member]
Profit loss before tax arrived after charging and crediting.
Related Parties
Related parties [member]
Disclosure of disaggregation of revenue from contracts with customers [abstract]
Disclosure Of Transaction Price Allocated To Remaining Performance Obligations [Table]
Disclosure of transaction price allocated to remaining performance obligations [table]
Other income and gains
Other Income And Gains [Abstract]
Other income and gains.
Intangible Assets [Roll Forward]
Intangible Assets [Roll Forward]
Intangible Assets
Vested during the year (in dollars per share)
Weighted average exercise price of other equity instruments exercised or vested in share-based payment arrangement
Cash received from withdrawal of financial assets measured at amortized cost
Cash received from withdrawal of financial assets measured at amortized cost
Cash received from withdrawal of financial assets measured at amortized cost
Increase/ (decrease) in the rate of foreign currency
Percentage Of Increase Decrease In Rate Of Foreign Currency
Percentage of increase (decrease) in the rate of foreign currency.
Impairment of non-financial assets
Description of accounting policy for impairment of non-financial assets [text block]
Decrease/ (increase) in loss before tax
Foreign exchange gain (loss)
Europe
Europe [Member]
Current
Current tax relating to items credited (charged) directly to equity
2023/05/08 - 2032/05/07
2023/05/08 - 2032/05/07 [Member]
2023/05/08 - 2032/05/07
PO1: First Twelve Months of Expenses
Performance Obligation 1, First Twelve Months Of Expenses [Member]
Performance Obligation 1, First Twelve Months Of Expenses
Decrease/(increase) in other non-current assets
Adjustments for decrease (increase) in other non-current assets
Adjustments for decrease (increase) in other non-current assets
Hainan Chuanji Biotechnology Co., Ltd. (“Hainan Chuanji”)
Hainan Chuanji Biotechnology Co Ltd [Member]
Hainan Chuanji Biotechnology Co., Ltd.
Equity-settled share-based compensation expense
Equity-settled share-based compensation expense
Expense from share-based payment transactions with employees
CURRENT ASSETS
Current assets [abstract]
Non-cash additions to right-of-use assets
Non Cash Additions To Right Of Use Assets
Non-cash additions to right-of-use assets.
Categories of related parties [axis]
Categories of related parties [axis]
Collaboration assets
Collaboration Assets Leased
Collaboration Assets [Member]
Collaboration Assets
2023/08/02 - 2032/08/01
2023/08/02 - 2032/08/01 [Member]
2023/08/02 - 2032/08/01
Related parties
Description of accounting policy for transactions with related parties [text block]
CARTITUDE-1 Clinical Trial
CARTITUDE-1 Clinical Trial [Member]
CARTITUDE-1 clinical trial.
Reclassification of vesting of restricted share units (in shares)
Reclassification Of Vested Restricted Stock Units Number Of Shares In Issue
Reclassification of vested restricted stock units, number of shares in issue.
Statement Of Changes In Equity [Line Items]
Statement of changes in equity [line items]
Classes of financial assets [axis]
Classes of financial assets [axis]
Profit (loss) [abstract]
Issuance of ordinary shares for exercise of warrants (in shares)
Issuance Of Ordinary Shares For Exercise Of Warrants, Shares
Issuance Of Ordinary Shares For Exercise Of Warrants, Shares
Financial assets measured at fair value through profit and loss
Financial assets at fair value through profit or loss, category [member]
Analyzed into:
Lease liabilities [abstract]
Effect of tax rate differences in other countries and regions
Tax effect of foreign tax rates
Entity File Number
Entity File Number
Submission of NDA
NDA Submission [Member]
NDA Submission
CASH FLOWS FROM INVESTING ACTIVITIES
Cash flows from (used in) investing activities [abstract]
LOSS FOR THE YEAR
Loss for the year
Profit (loss)
2023/04/30 - 2032/04/29
2023/04/30 - 2032/04/29 [Member]
2023/04/30 - 2032/04/29
Price per share (in dollars per share)
Authorized, price per share (in dollars per share)
Issued and fully paid, price per share (in dollars per share)
Par value per share
Expense relating to short-term leases
Expense relating to short-term leases for which recognition exemption has been used
Auditor Firm ID
Auditor Firm ID
Cash used in operations
Cash flows from (used in) operations
Entity Shell Company
Entity Shell Company
FINANCIAL INSTRUMENTS BY CATEGORY
Disclosure of detailed information about financial instruments [text block]
Income tax
Description of accounting policy for income tax [text block]
Number of milestone payments
Number Of Milestone Payments
Number of milestone payments.
WARRANT LIABILITY
Disclosure Of Warrant Liability Explanatory [Text Block]
Disclosure of warrant liability explanatory.
Transaction price, total aggregate reimbursable development costs (up to)
Maximum Additional Transaction Price
Maximum Additional Transaction Price
Summary of Assets Measured at Fair Value
Disclosure of fair value measurement of assets [text block]
Payable for Collaboration Assets
Payable For Collaboration Assets
Payable For Collaboration Assets
Work-in-process
Current work in progress
Ongoing lease payments
Ongoing Lease Payments Under The Land Lease
Ongoing lease payments under the land lease.
Underlying stock price (in dollars per share)
Exercise price, share options granted
Proceeds from exercise of share options
Proceeds from exercise of options
Statement of changes in equity [abstract]
Future estimated milestone payments
Future estimated milestone payments (up to)
Future Estimated Milestone Payments
Estimated milestone payments to be received
Counterparties [axis]
Counterparties [axis]
Contact Personnel Name
Contact Personnel Name
Subsidiaries
Subsidiaries [member]
Income tax rate
Applicable tax rate
BASIS OF PREPARATION
Disclosure of basis of preparation of financial statements [text block]
Share capital
Share Capital [Member]
Share capital.
Major components of tax expense (income) [abstract]
Document Registration Statement
Document Registration Statement
Entity Address, Address Line One
Entity Address, Address Line One
Entity Address, Address Line Two
Entity Address, Address Line Two
Trade payables, term
Trade Payables Term
Trade payables, term.
Inventory reserve
Inventory reserve
Inventory reserve
Taxable income
Accounting profit
Assets [member]
Assets [member]
Summary Of Significant Accounting Policies [Abstract]
Summary of significant accounting policies.
OTHER NON-CURRENT ASSETS
Disclosure of other non-current assets [text block]
Leasehold improvement
Leasehold improvements [member]
Lease liabilities
Current portion
Current lease liabilities
Equity-settled share-based compensation expense
Increase (decrease) through share-based payment transactions, equity
Disclosure Of Detailed Information About Borrowings [Line Items]
Disclosure of detailed information about borrowings [line items]
Provisions
Provisions Policy [Text Block]
Provisions
Share-based payments
Description of accounting policy for share-based payment transactions [text block]
Attributable to:
Profit (loss), attributable to [abstract]
2019/12/25 – 2027/12/25
2019/12/25 – 2027/12/25 [Member]
2019/12/25 – 2027/12/25
Use of Estimates
Description Of Use Of Estimates Policy [Policy Text Block]
Description Of Use Of Estimates Policy
CASH FLOWS FROM OPERATING ACTIVITIES
Cash flows from (used in) operating activities [abstract]
Preferential tax rate in other countries and regions
Tax Effect Of Foreign Preferential Tax Rates
Tax Effect Of Foreign Preferential Tax Rates
Within 1 year
Less than 1 years
Not later than one year [member]
Leases
Description of accounting policy for leases [text block]
Share option expense
Expenses Recognized For Share Options
Expenses recognized for share options.
Over 1 years
Later than one year [member]
Summary of Changes in Liabilities Arising from Financing Activities
Disclosure of reconciliation of liabilities arising from financing activities [text block]
Capital commitments [abstract]
Trade payables
Trade payables
Total current assets
Current assets
Collaboration agreement, number of performance obligations
Collaboration Agreement, Number of Performance Obligations
Collaboration Agreement, Number of Performance Obligations
Beginning balance
Ending balance
Share Capital And Share Premium
Share capital and share premium.
Other income:
Income, Other [Abstract]
Income, Other
Disposal
Increase Decrease Through Disposal Liabilities Arising From Financing Activities
Increase (decrease) through disposal, liabilities arising from financing activities.
Entity Addresses, Address Type
Entity Addresses, Address Type [Axis]
Entity Common Stock, Shares Outstanding
Entity Common Stock, Shares Outstanding
Disclosure Of Classes Of Share Capital [Table]
Disclosure of classes of share capital [table]
At the statutory blended US federal and state income tax rate of 24.3% (2022 and 2021: 28.1%)
Statutory Blended Income Tax Rate
Statutory blended income tax rate.
Classes of intangible assets other than goodwill [axis]
Classes of intangible assets other than goodwill [axis]
Nanjing Legend Biotechnology Co., Ltd. (“Legend Nanjing”)
Legend Nanjing
Nanjing Legend Biotechnology Co Ltd [Member]
Nanjing Legend Biotechnology Co Ltd.
Disclosure Of Number And Weighted Average Remaining Contractual Life Of Outstanding Share Options [Line Items]
Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]
Risk-free interest rate (%)
Risk free rate
Risk free interest rate, share options granted
Additional share capital amount
Additional Share Capital Amount
Additional share capital amount.
Disclosure Of Prepayments Other Receivables And Other Assets [Line Items]
Disclosure Of Prepayments Other Receivables And Other Assets [Line Items]
Disclosure of prepayments, other receivables and other assets.
Entity Address, State or Province
Entity Address, State or Province
Fair value gains on financial assets measured at fair value change through profit or loss
Gains (losses) on financial assets at fair value through profit or loss
Issuance of ordinary shares for exercise of warrants
Issuance Of Ordinary Shares For Exercise Of Warrants
Issuance Of Ordinary Shares For Exercise Of Warrants
Reclassification of vesting of restricted share units
Reclassification Of Vested Restricted Stock Units Share Capital And Share Premium
Reclassification of vested restricted stock units, share capital and share premium.
Effective interest rate
Borrowings, interest rate
Concentrations of risk [member]
Concentrations of risk [member]
Private placement purchase price per share (in dollars per share)
Exercise Price Per Ordinary Share
Exercise price per ordinary share.
Liabilities arising from financing activities [member]
Liabilities arising from financing activities [member]
Other receivables
Other Receivables [Member]
Other receivables.
Disclosure Of Financial Instruments [Table]
Disclosure of detailed information about financial instruments [table]
Trade receivables
Trade receivables [member]
Summary of Movements in the Company's Share Capital and Share Premium
Disclosure Of Movements In Company S Share Capital And Share Premium Explanatory [Table Text Block]
Disclosure of movements in the company's share capital and share premium explanatory.
Trade And Notes Payables [Line Items]
Trade And Notes Payables Line Item
Trade and notes payables.
Raw materials
Current raw materials
Disclosure Of Financial Liabilities [Table]
Disclosure of financial liabilities [table]
Lease receivables
Lease receivables
Finance lease receivables
CARTITUDE-5 Clinical Trial
Marketing Authorization Submission, CARTITUDE-5 Clinical Trial, And Drug Approval Application [Member]
Marketing Authorization Submission, CARTITUDE-5 Clinical Trial, And Drug Approval Application
Investments and other financial assets
Description Of Accounting Policy For Investments And Other Financial Assets Explanatory [Policy Text Block]
Description of accounting policy for investments and other financial assets.
Disclosure of Outstanding Balances with Related Parties Explanatory
Disclosure Of Outstanding Balances With Related Parties Explanatory [Table Text Block]
Disclosure of outstanding balances with related parties.
Ordinary equity holders of the parent
Comprehensive income, attributable to owners of parent
Disclosure of subsidiaries [abstract]
Prepayments, Other Receivable and Other Assets
Prepayments Other Receivables And Other Assets [Member]
Prepayments other receivables and other assets.,
Advance payments for property, plant and equipment
Advance Payments For Property Plant And Equipment
Advance payments for property, plant and equipment.
Categories of current financial assets [abstract]
Profit Loss Before Tax [Line Items]
Profit Loss Before Tax [Line Items]
Line items represent profit loss before tax.
Issuance of ordinary shares
Issue of equity
Interest income received
Finance income received, classified as operating activities
COLLABORATION INTEREST-BEARING ADVANCED FUNDING
Disclosure of borrowings [text block]
Tax losses
Deferred tax expense (income)
Measurement [axis]
Measurement [axis]
Prepayments, other receivables and other assets
Current prepayments and other current assets
Property, plant and equipment, and depreciation
Description of accounting policy for property, plant and equipment [text block]
Deferred tax liabilities, beginning balance
Deferred tax liabilities, ending balance
Deferred tax liabilities
Disclosure Of Reconciliation Of Liabilities Arising From Financing Activities [Table]
Disclosure of reconciliation of liabilities arising from financing activities [table]
Credit period of trade receivables
Credit Period Of Trade Receivables
Credit period of trade receivables.
2023/06/30 - 2032/06/29
2023/06/30 - 2032/06/29 [Member]
2023/06/30 - 2032/06/29
Right-of-Use Assets [Roll Forward]
Right-of-Use Assets [Roll Forward]
Right-of-Use Assets
Total revenue and other revenue
Revenue from contracts with customers
Types of share-based payment arrangements [axis]
Types of share-based payment arrangements [axis]
Addition in time deposits
Addition In Time Deposits
Addition in time deposits.
Bottom of Range
Bottom of range [member]
Principal portion of lease payments
Payments of lease liabilities, classified as financing activities
Issuance of ordinary shares for private placements, net of issuance cost (in shares)
Issuance Of Ordinary Shares Relating To Private Placement For Institutional Investor Number Of Shares Issue
Issuance of ordinary shares relating to private placement for institutional investor number of shares issue.
Non-cash additions to property, plant and equipment
Non Cash Additions To Property Plant And Equipment
Non-cash additions to property, plant and equipment.
Country of incorporation
Country of incorporation
Other tax payables
Other Tax Payables
Other tax payables,
Licensing of patents to related parties
Revenue From Licensing Of Patents Related Party Transactions
Revenue from licensing of patents related party transactions.
Summary of Cash and Cash Equivalents, Time Deposits and Pledged Deposits
Disclosure Of Detailed Information About Cash And Cash Equivalents Time Deposits And Pledged Deposits Explanatory [Table Text Block]
Disclosure of detailed information about cash and cash equivalents, time deposits and pledged deposits.
Non-cash additions to lease liabilities
Additions of lease liabilities
Increase through new leases, liabilities arising from financing activities
Exchange realignment
Foreign exchange movement
Increase (decrease) through effect of changes in foreign exchange rates, liabilities arising from financing activities
Warranty Liabilities [Roll Forward]
Warranty Liabilities [Roll Forward]
Warranty Liabilities
Entity Filer Category
Entity Filer Category
Cash and cash equivalents as stated in the statement of cash flows
Cash And Cash Equivalents As Stated In Statement Of Cash Flows
Cash and cash equivalents as stated in statement of cash flows.
Ordinary Shares
Ordinary Shares
Ordinary shares [member]
Current Fiscal Year End Date
Current Fiscal Year End Date
OTHER PAYABLES AND ACCRUALS
Disclosure Of Other Payables And Accruals Explanatory [Text Block]
Disclosure of other payables and accruals.
Address Type
Address Type [Domain]
Retained earnings/(accumulated losses)
Retained earnings [member]
Classes of property, plant and equipment [axis]
Classes of property, plant and equipment [axis]
Adjustments for:
Adjustments to reconcile profit (loss) [abstract]
Leases [Table]
Leases [Table]
Leases table.
Financial assets at fair value through profit or loss
Description of accounting policy for financial instruments at fair value through profit or loss [text block]
Financial assets included in prepayments, other receivables and other assets (note 16)
Financial Assets Included In Prepayments Other Receivables And Other Assets [Member]
Financial assets included in prepayments, other receivables and other assets.
Restricted Scheme
Restricted Stock Plan [Member]
Restricted stock plan.
Schedule of Movement of Warrant Liability
Disclosure Of Detailed Information About Warrant Liability Explanatory [Table Text Block]
Disclosure of detailed information about warrant liability explanatory.
Proceeds from upfront fees recognized as revenue
Proceeds From Upfront Fees Recognized As Revenue
Proceeds From Upfront Fees Recognized As Revenue
Genscript Probio USA Inc
Genscript Probio U S A Inc [Member]
Genscript Probio U S A Inc
Deferred tax carry back period
Deferred Tax Carry Back Period
Deferred tax carry back period.
Amortization of intangible assets
Adjustments for amortisation expense
Basis Of Preparation [Abstract]
Basis of Preparation.
Denominated in EUR
Euro Member Countries, Euro
Fair value (loss)/gain of warrant liability
Fair Value Loss Of Warrants Liabilities
Fair value loss of warrant liabilities.
Additions
Additions other than through business combinations, intangible assets other than goodwill
Collaboration interest-bearing advanced funding
Collaboration Interest-Bearing Advanced Funding
Collaboration Interest-Bearing Advanced Funding
Disclosure Of Operating Segments [Line Items]
Disclosure of operating segments [line items]
Legend Biotech Limited (“Legend BVI”)
Legend Biotech Limited [Member]
Legend Biotech Limited.
Intangible assets other than goodwill [member]
Intangible assets other than goodwill [member]
LOSS PER SHARE ATTRIBUTABLE TO ORDINARY EQUITY HOLDERS OF THE PARENT
Earnings per share [abstract]
Summary of Maturity Profile of Financial Liabilities Based on Contractual Undiscounted Payments
Disclosure of maturity analysis for financial assets held for managing liquidity risk [text block]
Non-trading income tax rate
Non Trading Income Tax Rate
Non trading income tax rate.
Government grant received
Adjustments For Government Grant Received
Adjustments for government grant received.
Nanjing GenScript Biotech Co., Ltd.
Nanjing GenScript Biotech Co., Ltd. [Member]
Nanjing GenScript Biotech Co., Ltd. (formerly named as Nanjing Jinsirui Biotechnology Co., Ltd.)
Finance costs
Adjustments for finance costs
Total income
Other income
Levels of fair value hierarchy [axis]
Levels of fair value hierarchy [axis]
Compensation fee for termination of service agreement
Compensation Fee For Termination Of Service Agreement
Compensation fee for termination of service agreement.
Disclosure Of Financial Instruments [Line Items]
Disclosure of detailed information about financial instruments [line items]
Statement Of Changes In Equity [Table]
Statement of changes in equity [table]
Capital Management
Equity price risk [member]
Net cash used in operating activities
Cash flows from (used in) operating activities
Document Fiscal Period Focus
Document Fiscal Period Focus
Loans from a collaborator
Non-current portion of non-current loans received
(Increase)/decrease in prepayments, other receivables and other assets
Adjustments For Decrease Increase In Prepayments Other Receivable Other Assets
Adjustments for decrease increase in prepayments other receivable other assets.
Summary of Total Cash Outflow for Leases Included in Statement of Cash Flows
Disclosure Of Total Cash Outflow For Leases Included In Statement Of Cash Flows Explanatory [Table Text Block]
Disclosure of total cash outflow for leases included in statement of cash flows explanatory.
Revenue recognition
Description of accounting policy for recognition of revenue [text block]
Weighted average exercise price
Weighted Average Exercise Price [Roll Forward]
Weighted Average Exercise Price
If US$ weakens against RMB
U S Dollar Weakens Against R M B [Member]
US$ weakens against RMB.
City Area Code
City Area Code
Interest rate margin percentage
Borrowings, adjustment to interest rate basis
Summary of Analysis of Revenue
Disclosure of disaggregation of revenue from contracts with customers [text block]
Document Fiscal Year Focus
Document Fiscal Year Focus
Geographical
Geographical [Domain]
Foreign Currency Risk
Currency risk [member]
Tax expense (income), effective tax rate [Abstract]
Tax expense (income), rate [Abstract]
Tax expense (income), rate
Disclosure of non-adjusting events after reporting period [abstract]
Summary of Non-current Assets
Disclosure Of Non Current Asset Information [Text Block]
Disclosure of non-current asset Information.
Warrant liability
Current derivative financial liabilities
Major Components Of Tax Expense Income [Table]
Major Components Of Tax Expense Income [Table]
Major components of tax expense income.
Fair value loss/(gain) of warrant liability
Non-cash fair value loss (gain) of warrant liability
Adjustment For Fair Value Loss (Gain) Of Warrant Liability
Adjustment for fair value loss (gain) of warrant liability.
Deferred government grants
Government grants
Disclosure Of Financial Assets [Table]
Disclosure of financial assets [table]
Stock Option and Restricted Stock Unit Scheme
Share Option And Restricted Stock Unit Scheme [Member]
Share option and restricted stock unit scheme.
Research and development expenses
Research and development expense
Registered Direct Offering
Registered Direct Offering [Member]
Registered Direct Offering
Number of batches of funding advances
Number Of Borrowing Batches
Number Of Borrowing Batches
Summary of Fair Value of Equity Settled Share Options Granted
Disclosure of indirect measurement of fair value of goods or services received, share options granted during period [text block]
Deferred government grant
Deferred Government Grant
Deferred government grant.
Withholding tax percentage
Withholding Tax Percentage
Withholding tax percentage.
Pledged deposits
Pledged Deposits
Pledged deposits.
Summary of Financial Assets
Disclosure of financial assets [text block]
Borrowings by name [member]
Borrowings by name [member]
Exchange differences on translation of foreign operations
Other comprehensive income, net of tax, exchange differences on translation of foreign operations
Share-based compensation reserves
Reserve of share-based payments [member]
License revenue
Licensing of intellectual property
Revenue From Licensing Of Intellectual Property
Revenue from licensing of intellectual property.
Purchases from related parties
Purchases of goods, related party transactions
Currency
Currency [Axis]
Entity Address, City or Town
Entity Address, City or Town
Right-of-use assets
Beginning balance
Ending balance
Right-of-use assets
Carrying amount at January 1
Carrying amount at December 31
Total
Lease liabilities
Lease liabilities
Total
Financial liabilities
REVENUE
Revenue [abstract]
CHANGES IN ACCOUNTING POLICIES AND DISCLOSURES
Disclosure of voluntary change in accounting policy [text block]
Denominated in RMB
China, Yuan Renminbi
Leases [Line Items]
Leases [Line Items]
Leases line items.
Increase/(decrease) in contract liabilities (non-current)
Adjustments For Increase (Decrease) In Contract Liabilities, Non-Current
Adjustments For Increase (Decrease) In Contract Liabilities, Non-Current
Government Grant [Abstract]
Government grant.
Disclosure Of Fair Value Valuation Of Warrant Liability [Abstract]
Disclosure of fair value valuation of warrant liability.
Schedule of Profit (Loss) Before Tax Arrived After Charging
Disclosure Of Profit Loss Before Tax Arrived After Charging [Table Text Block]
The disclosure of profit loss before tax arrived after charging and crediting.
Elsewhere
Other Than U S [Member]
Other than U.S.
Other payables and accruals
Other payables and accruals
Other payables
Other Payables And Accruals Current
Other payables and accruals, current.
Document Information [Table]
Document Information [Table]
Trade And Notes Payables [Table]
Trade And Notes Payables [Table]
Trade and notes payables.
Additions
Additions other than through business combinations, property, plant and equipment
Significant observable inputs (Level 2)
Level 2 of fair value hierarchy [member]
Liabilities arising from financing activities [axis]
Liabilities arising from financing activities [axis]
Tax expense (income), amount [Abstract]
Tax expense (income), amount [Abstract]
Tax expense (income), amount
Specified manufacturing milestones
Specified Manufacturing Milestones [Member]
Specified manufacturing milestones.
Cost recovery of R&D expense
Cost Recovery of Researched and Development Expense [Member]
Cost Recovery of Researched and Development Expense
Description Of Expected Impact Of Initial Application Of New Standards Or Interpretations [Table]
Disclosure of expected impact of initial application of new standards or interpretations [table]
LEASES
Disclosure of leases [text block]
(Decrease)/increase in other payables and accruals
Adjustments for increase (decrease) in other operating payables
PO2: Supply of materials
Performance Obligation 2 [Member]
Performance Obligation 2
Summary of Movement in Number of RSU Outstanding
Disclosure of number and weighted average exercise prices of other equity instruments [text block]
Summary of Transaction Price and Performance Obligations
Disclosure of performance obligations [text block]
Document Information [Line Items]
Document Information [Line Items]
Percentage of equity interest attributable to the Company
Proportion of ownership interest in subsidiary
Description Of Expected Impact Of Initial Application Of New Standards Or Interpretations [Line Items]
Disclosure of expected impact of initial application of new standards or interpretations [line items]
Disclosure Of Detailed Information About Lease Liabilities [Line Items]
Disclosure Of Detailed Information About Lease Liabilities [Line Items]
Disclosure of detailed information about lease liabilities.
Additions
Additions to right-of-use assets
Purchase of property, plant and equipment
Purchase of property, plant and equipment, classified as investing activities
Exercisable at December 31 (in shares)
Number of share options exercisable in share-based payment arrangement
Jiangsu GenScript Biotech Co., Ltd.
Jiangsu GenScript Biotech Co., Ltd. [Member]
Jiangsu GenScript Biotech Co., Ltd.
Subsidiaries [axis]
Subsidiaries [axis]
Capital requirements [member]
Capital requirements [member]
Entity Registrant Name
Entity Registrant Name
2024/04/03 - 2033/04/02
2024/04/03 - 2033/04/02 [Member]
2024/04/03 - 2033/04/02
Temporary difference, unused tax losses and unused tax credits [axis]
Temporary difference, unused tax losses and unused tax credits [axis]
Auditor Name
Auditor Name
FINANCE COSTS
Entire Disclosure Of Finance Costs Explanatory [Text Block]
The entire disclosure of finance costs.
Reconciliation Of Changes In Deferred Tax Assets and Liabilities [Table]
Reconciliation Of Changes In Deferred Tax Assets and Liabilities [Table]
Reconciliation of changes in deferred tax assets and liabilities table.
Exercise of the warrant liability
Exercise Of The Warrant Liability
Exercise Of The Warrant Liability
Counterparties [member]
Counterparties [member]
Collaboration Arrangements
Description of accounting policy for collaboration arrangements [Text Block]
Description of accounting policy for collaboration arrangements
Entity Central Index Key
Entity Central Index Key
Total
Deferred Tax Asset Not Yet Recognized
Deferred tax asset not yet recognized.
Disclosure Of Classes Of Share Capital [Line Items]
Disclosure of classes of share capital [line items]
Schedule of Property, Plant and Equipment
Disclosure of detailed information about property, plant and equipment [text block]
Decrease in time deposits
Decrease In Time Deposits
Decrease in time deposits.
PO1: Up-Front Payment
Performance Obligation 1, Up-Front Payment [Member]
Performance Obligation 1, Up-Front Payment
Financial liabilities included in other payables and accruals (note 19)
Financial Liabilities Included In Other Payables And Accruals [Member]
Financial liabilities included in other payables and accruals.
Exercise price per share (in dollars per share)
Exercise price of outstanding share options
New Jersey
NEW JERSEY
2021/11/19 – 2030/11/18
2021/11/19 – 2030/11/18 [Member]
2021/11/19 – 2030/11/18
Property, Plant and Equipment [Roll Forward]
Property, Plant and Equipment [Roll Forward]
Property, Plant and Equipment
Cash and cash equivalents as stated in the statement of financial position
Cash And Cash Equivalents As Stated In Statement Of Financial Position
Cash and cash equivalents as stated in statement of financial position.
Other employee benefits
Other employee expense
Total
Prepayments Other Receivables And Other Assets
Prepayments, other receivables and other assets.
Prepayment to collaborator for collaboration assets
Prepayment To Collaborator For Collaboration Right Of Use Assets
Prepayment To Collaborator For Collaboration Right Of Use Assets
Deferred tax charged/(credited) to the statement of profit or loss during the year
Deferred tax expense (income) recognised in profit or loss related to deferred tax liabilities
Deferred tax expense (income) recognised in profit or loss related to deferred tax liabilities
Accrued expense
Accrued Expense [Member]
Accrued Expense
Transfer Of Intellectual Property License
Transfer Of Intellectual Property License [Member]
Transfer Of Intellectual Property License
Geographical areas [member]
Geographical areas [member]
Trade receivables
Upfront fee receivable
Current trade receivables
Exercise period
Warrant Exercise Period
Warrant Exercise Period
Number of shares issued (in shares)
Ordinary shares, purchased (in shares)
Number of shares issued
Equity [member]
Equity [member]
Amendment Flag
Amendment Flag
SIGNIFICANT ACCOUNTING JUDGEMENTS AND ESTIMATES
Disclosure of accounting judgements and estimates [text block]
FINANCIAL RISK MANAGEMENT OBJECTIVES AND POLICIES
Disclosure of financial instruments [text block]
Other payables due to related parties
Payables to related parties
Accumulated depreciation
Accumulated depreciation
Accumulated depreciation
Selling and distribution expenses
Selling And Distribution Expenses
Selling and distribution expenses.
2023/05/10 - 2032/05/09
2023/05/10 - 2032/05/09 [Member]
2023/05/10 - 2032/05/09
Increase/(decrease) in other non-current liabilities
Adjustments For Increase Decrease In Other Non Current Liabilities
Adjustments for increase (decrease) in other non current liabilities.
Disclosure Of Cash And Cash Equivalents Time Deposits And Pledged Deposits [Table]
Disclosure Of Cash And Cash Equivalents Time Deposits And Pledged Deposits [Table]
Disclosure of cash and cash equivalents, time deposits and pledged deposits.
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Disclosure of significant accounting policies [text block]
The entire disclosure for significant accounting policies applied by the entity.
2021/06/05 – 2030/06/04
2021/06/05 – 2030/06/04 [Member]
2021/06/05 – 2030/06/04
INTANGIBLE ASSETS
Disclosure of intangible assets [text block]
Percentage of options outstanding
Percentage Of Outstanding Share Options
Percentage of outstanding share options.
Leases [Roll Forward]
Leases [Roll Forward]
Leases
Other income and gains
Total other income and gains
Other Income And Gains
Other income and gains.
Outstanding at January 1 (in shares)
Outstanding at December 31 (in shares)
Number of RSU, outstanding (in shares)
Number of other equity instruments outstanding in share-based payment arrangement
Carrying amount [member]
Carrying amount [member]
Milestone payments recognized as revenue
Proceeds from Milestone Payments
Milestone payments.
Information About Subsidiaries
Disclosure of subsidiaries [text block]
Restricted Stock Units [Abstract]
Restricted stock units.
Disposals
Disposals, property, plant and equipment
Funding advances from collaborator principal amount
Borrowings
Disclosure Fair Value Measurement Hierarchy Of Financial Instruments [Table]
Disclosure Fair Value Measurement Hierarchy Of Financial Instruments [Table]
Disclosure fair value measurement hierarchy of financial instruments.
Summary of Undiscounted Minimum Lease Payments Receivables for Leases
Disclosure of maturity analysis of finance lease payments receivable [text block]
PO1: Licensing of intellectual property and completion of Legend Phase 1 trial
Performance Obligation 1 [Member]
Performance Obligation 1
Within operating activities
Cash Outflow For Leases Within Operating Activities
Cash outflow for leases within operating activities.
Proceeds from exercise of warrant by warrant holder, net of issuance cost
Proceeds From Exercise Of Warrant By Warrant Holder, Net Of Issuance Cost
Proceeds From Exercise Of Warrant By Warrant Holder, Net Of Issuance Cost
Outstanding at January 1 (in dollars per share)
Outstanding at December 31 (in dollars per share)
Weighted average exercise price of other equity instruments outstanding in share-based payment arrangement
CASH AND CASH EQUIVALENTS, TIME DEPOSITS AND PLEDGED DEPOSITS
Disclosure of cash and cash equivalents [text block]
Patents
Copyrights, patents and other industrial property rights, service and operating rights [member]
Income tax rate on remaining assessable profits
Applicable Tax Rate On Remaining Assessable Profits
Applicable tax rate on remaining assessable profits.
2021/09/01 – 2030/08/31
2021/09/01 – 2030/08/31 [Member]
2021/09/01 – 2030/08/31
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Table]
Disclosure of terms and conditions of share-based payment arrangement [table]
Transaction Price Amounts Allocated to Remaining Performance Obligations
Disclosure of transaction price allocated to remaining performance obligations [text block]
Forfeited during the year (in shares)
Number of other equity instruments forfeited in share-based payment arrangement
Classes of assets [axis]
Classes of assets [axis]
Purchase of intangible assets
Purchase of intangible assets, classified as investing activities
After 4 years
Later Than Four Years [Member]
Later Than Four Years
Proceeds from disposal of property, plant and equipment
Proceeds from disposals of property, plant and equipment, intangible assets other than goodwill, investment property and other non-current assets
Foreign Currency Transactions and Foreign Currency Translation
Description of accounting policy for foreign currency translation [text block]
Other employee benefits
Description of accounting policy for employee benefits [text block]
Interest accrued on funding advances
Interest Bearing Borrowings Funded Interests Accrued
Interest bearing borrowings funded interests accrued.
LOSS BEFORE TAX
Loss before tax
Profit (loss) before tax
Disclosure Of Quantitative Information About Rightofuse Assets [Table]
Disclosure of quantitative information about right-of-use assets [table]
Freehold land
Leasehold land
Land [member]
Address of entity's registered office
Address of entity's registered office
Summary of Items with Respect to, Deferred Tax Assets have not been Recognized
Disclosure Of Detailed Information About Deferred Tax Assets Explanatory [Table Text Block]
Disclosure of detailed information about deferred tax assets.
GOVERNMENT GRANTS
Disclosure of government grants [text block]
Financing from follow-on public offering, net of issuance cost
Financing From Follow On Public Offering Net Of Issuance Cost
Financing from follow-on public offering, net of issuance cost.
Net cash provided by/(used in) investing activities
Cash flows from (used in) investing activities
Intangible assets
Net carrying amount, beginning balance
Net carrying amount, ending balance
Intangible assets other than goodwill
ANALYSIS OF BALANCES OF CASH AND CASH EQUIVALENTS
Cash and cash equivalents [abstract]
Exchange realignment
Increase (decrease) through net exchange differences, intangible assets other than goodwill
Outstanding foreign currency forward exchange contracts
Outstanding Foreign Currency Forward Exchange Contracts
Outstanding foreign currency forward exchange contracts.
All levels of fair value hierarchy [member]
All levels of fair value hierarchy [member]
Carrying amount, accumulated depreciation, amortisation and impairment and gross carrying amount [axis]
Carrying amount, accumulated depreciation, amortisation and impairment and gross carrying amount [axis]
Major customers [axis]
Major customers [axis]
Janssen
Janssen [Member]
Janssen
Issued and fully paid:
Number of shares issued [abstract]
Finance Costs [Abstract]
Finance costs.
Exercise of share options
Exercise Of Share Option
Exercise of share option.
SUBSEQUENT EVENT
Disclosure of events after reporting period [text block]
Government grants
Current
Current government grants